Select Publications

Divergent effects of acute and chronic PPT1 inhibition in melanoma. Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK. Autophagy. 2025 Feb;21(2):394-406. doi: 10.1080/15548627.2024.2403152. Epub 2024 Sep 19. PMID: 39265628; PMCID: PMC11760279.

Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistant NRAS-mutant melanoma. Lipchick B, Guterres AN, Chen HY, Zundell DM, Del Aguila S, Reyes-Uribe PI, Tirado Y, Basu S, Yin X, Kossenkov AV, Lu Y, Mills GB, Liu Q, Goldman AR, Murphy ME, Speicher DW, Villanueva J. Sci Transl Med. 2025 Feb 5;17(784):eadp8913. doi: 10.1126/scitranslmed.adp8913. Epub 2025 Feb 5. PMID: 39908352.

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X. Sci Adv. 2025 Jan 17;11(3):eadp9009. doi: 10.1126/sciadv.adp9009. Epub 2025 Jan 15. PMID: 39813334; PMCID: PMC11734719.

Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival. Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Clin Cancer Res. 2024 Sep 9. doi: 10.1158/1078-0432.CCR-23-3775. Epub ahead of print. PMID: 39248505.

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Cancer Cell. 2024 Aug 26:S1535-6108(24)00306-4. doi: 10.1016/j.ccell.2024.08.007. Epub ahead of print. PMID: 39214097.

LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali DAA, Wherry EJ. Cell. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018. PMID: 39121847.

FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD. Clin Cancer Res. 2024 Jan 24.

Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W. Cell Rep. 2023 Oct 31.

Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, Luo R, Elder DE, Huang AC, Karakousis G, Miura J, Mitchell T, Schuchter L, Amaravadi R, Flowers A, Mou H, Yi F, Guo W, Ko J, Chen Q, Tian B, Herlyn M, Xu X. EBioMedicine. 2023 Jun.

Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TC. Cancer Res Commun. 2023 May 9;3(5):821-829. doi: 10.1158/2767-9764.CRC-22-0486. PMID: 37377890; PMCID: PMC10167933.

Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis. Sharon CE, Straker RJ 3rd, Gimotty PA, Chu EY, Mitchell TC, Miura JT, Marchetti MA, Bartlett EK, Karakousis GC. J Am Acad Dermatol. 2023 Apr.

Shared and distinct biological circuits in effector, memory and exhausted CD8⁺ T cells revealed by temporal single-cell transcriptomics and epigenetics. Giles JR, Ngiow SF, Manne S, Baxter AE, Khan O, Wang P, Staupe R, Abdel-Hakeem MS, Huang H, Mathew D, Painter MM, Wu JE, Huang YJ, Goel RR, Yan PK, Karakousis GC, Xu X, Mitchell TC, Huang AC, Wherry EJ. Nat Immunol. 2022 Nov;23(11):1600-1613. doi: 10.1038/s41590-022-01338-4. Epub 2022 Oct 21. PMID: 36271148; PMCID: PMC10408358.

Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, Tsyganova S, Pisarev V, Laufer T, Ignatov D, Ferrone S, Meyer C, Maby-El Hajjami H, Speiser DE, Altiok S, Antonia S, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Yuan Z, Montaner LJ, Celis E, Gabrilovich DI. Cancer Cell. 2022 Oct 10.

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. PMID: 35902637; PMCID: PMC9880663.

BAMM (BRAF autophagy and MEK inhibition in melanoma): A phase I/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK. Clin Cancer Res. 2022 Mar 15.

Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Huang AC, Shi J, Wherry EJ. Immunity. 2022 Mar 8;55(3):557-574.e7. doi: 10.1016/j.immuni.2022.02.004. PMID: 35263570; PMCID: PMC9214622.

ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, Dong H, Gimotty PA, Daaboul G, Xu X, Guo W. Dev Cell. 2022 Feb 7.

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. Oncogene. 2021 Sep.

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Wherry EJ. Immunity. 2020 May 19;52(5):825-841.e8. doi: 10.1016/j.immuni.2020.04.014. Epub 2020 May 11. PMID: 32396847; PMCID: PMC8360766.

TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ. Nature. 2019 Jul;571(7764):211-218. doi: 10.1038/s41586-019-1325-x. Epub 2019 Jun 17. PMID: 31207603; PMCID: PMC6713202.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D’Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. Nature Med. 2019.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Nature. 2018.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10. PMID: 28397821; PMCID: PMC5554367.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. PMID: 25754329; PMCID: PMC4401634.